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PANCREOX trial and second-line treatment after 
gemcitabine-based first-line
Pancreatic cancer is an extremely aggressive disease, 
projected to become the second leading cause of cancer-
related death (1). While the attempt of using a personalized 
approach in first line setting failed, the intensification of the 
treatment, by the use of the combination of gemcitabine 
and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) 
and the triplet regimen FOLFIRINOX (a combination 
of 5-fluorouracil (5-FU), leucovorin, irinotecan and 
oxaliplatin) have significantly improved the outcome of 
these patients (2-4). 
Given these results, the number of patients fit for a 
second-line treatment is significantly increasing and the 
identification of a standard second-line approach is urgently 
needed. Currently, there is no standard of treatment after 
FOLFIRINOX; in the French phase III study 80 patients in 
the FOLFIRINOX group and 85 patients in the gemcitabine 
group received a second-line treatment. In particular, in the 
“FOLFIRINOX group”, gemcitabine or a gemcitabine-based 
combination were administered in the majority of patients; 
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whereas in the “gemcitabine group” most patients were treated 
with combinations containing oxaliplatin or cisplatin (2). 
However, no difference in overall survival was noted between 
the two groups (i.e., 4.4 months each).
Data about the use of oxaliplatin in second-line setting 
derive from the results of the German CONKO-003 phase 
III randomized trial, firstly presented in 2008, and then with 
updated results in 2014 (5). This phase III trial was initially 
designed to compare folinic acid, fluorouracil administered 
weekly in 24-hour infusion for the first 4 weeks and 
oxaliplatin administered on days 8, 22 of a 6-week-cycle 
(OFF) versus best supportive care. However, because of the 
initial data about second-line treatment derived from phase 
II studies, the trial was modified and patients were randomly 
assigned to receive OFF or folinic acid and fluorouracil (FF). 
OFF resulted in a statistically significant increase in overall 
survival (5.9 vs. 3.3 months; P=0.010) and in progression-
free survival (2.9 vs. 2.0 months; P=0.019). The toxicity 
profile was not significantly different between the two arms 
and both FF and OFF resulted feasible in this pre-treated 
population, with the exception of grade 3 neuropathy that 
was present in three patients in OFF treatment while absent 
in FF treatment (5). Of note, only one patient in OFF 
arm experienced grade 3 thrombocytopenia, while none 
experienced grade 3 leucopenia; thus, 81% of oxaliplatin 
administrations were full dose. 
More recently, the PANCREOX trial has evaluated the 
potential advantage of the more widely used combination 
containing oxaliplatin and 5-fluorouracil as a bolus and 
in continuous infusion (m-FOLFOX 6 regimen) versus 
5-fluorouracil monotherapy (6), trying to confirm the 
role of oxaliplatin in the second-line setting. This study 
was closed after the enrollment of 108 patients before the 
target accrual of 128 patients; after a median follow-up of 
8.8 months no difference in progression-free survival (3.1 
vs. 2.9 months; P=0.989) was observed between the two 
arms, while, the median overall survival (OS) was lower in 
the m-FOLFOX6 arm than in the 5-fluorouracil alone arm 
(6.1 vs. 9.9 months; P=0.024).
The conflicting results from the CONKO-003 and 
the PANCREOX trials seem to undermine the role of 
oxaliplatin in pre-treated patients, but several important 
aspects of these trials should be considered more carefully. 
The most evident bias possibly affecting the results in 
PANCREOX trial is the adherence to the treatment: an 
overall incidence of grade 3–4 adverse events of 63% 
in FOLFOX arm can actually affect the results: 10% 
of permanent discontinuation was registered in this 
arm comparing to 0% of FU alone and almost half of 
the patients needed a dose reduction of oxaliplatin and 
5-fluorouracil due to hematologic toxicity or neuropathy. 
Remarkably, the patients randomized in the FOLFOX 
arm had worse general conditions than the patients treated 
with 5-fluorouracil one (11.1% vs. 5.7% had ECOG PS 2), 
however, patients treated with FOLFOX had a longer 
median time since the diagnosis of advanced disease (7.9 vs. 
5.7 months). 
Another interesting point is that a study withdrawal 
due to disease progression was more frequent in the 
5-fluorouracil/leucovorin arm (75% vs. 55%) while the 
cause was the development of adverse events in 20% of 
the patients treated with FOLFOX, versus 2% in patients 
treated with 5-fluorouracil/leucovorin.
Furthermore, among post-progression treatments, 
aggressive combinatory treatments were more frequently 
used after 5-fluorouracil/leucovorin than after FOLFOX. 
These therapeutic choices could have been influenced by 
adverse events experienced by patients and performance 
status at progressive disease. This might at least in part 
explain the overall survival in the 5-fluorouracil/leucovorin 
arm, which is extraordinarily long for second-line setting 
(i.e., 9.9 months).
A l though  compar i sons  be tween  OFF (5 )  and 
PANCREOX studies can be only speculative and not 
made according to correct statistical methodology, some 
additional considerations should be taken into account, 
as follows. Both of these trials were designed in the 
“gemcitabine-monotherapy era”, before the revolution 
given by FOLFIRINOX triplet regimen and gemcitabine 
and nab-paclitaxel doublet; only in the PANCREOX trial 
a proportion (25.9% in FOLFOX arm and 22.2% in the 
5-fluorouracil/leucovorin arm) of the patients had been 
treated with gemcitabine-based combinations, while in 
CONKO-003 trial all the patients had received gemcitabine 
monotherapy in first-line setting.
The most evident difference between the two trials is in 
the regimen used: the increased oxaliplatin intensity and the 
presence of the 5-fluorouracil bolus in PANCREOX trial 
may have played an important role in the results, suggesting 
a role of oxaliplatin in pre-treated patients, within an 
acceptable modulated schedule.
The use of oxaliplatin in second-line setting was also 
evaluated in a phase II Japanese study: patients were 
randomly assigned to receive S-1 monotherapy or S-1 in 
combination with oxaliplatin (SOX) after progression on 
a gemcitabine-based first-line chemotherapy. Despite the 
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increase in response rate, only a trend in favour of SOX was 
observed in progression-free survival and overall survival (7). 
Most recently, the NAPOLI-1 phase III trial enlarged 
the perspective of second-line treatment in gemcitabine-
pretreated patients. This was a large, multicenter trial, 
enrolling more than 400 patients, designed with three 
arms: nanoliposomal irinotecan plus fluorouracil and 
folinic acid, nanoliposomal irinotecan monotherapy or 
fluorouracil monotherapy (i.e., the same control arm as in 
the CONKO.003 trial). Patients had received gemcitabine-
based regimens also in neoadjuvant and adjuvant setting 
(if progressed within 6 months) and in advanced disease. 
Moreover, patients were selected for toxicity by the 
evaluation of UGTA1 genotype testing; the initial dose was 
reduced in case of homozygous result. 
Since the study was initially designed to have only 
two arms (nanoliposomal irinotecan monotherapy or 
5-fluorouracil monotherapy) and then amended to have 
three arms, a total of 151 patients were treated with 
nanoliposomal monotherapy, 149 patients with 5-fluorouracil 
and folinic acid and 117 patients with the combination, 
respectively. The primary endpoint was met: median overall 
survival was 6.1 months in the nanoliposomal irinotecan 
and 5-fluorouracil combination arm and 4.2 months 
in the fluorouracil and folinic acid arm (P=0.012), while 
overall survival was 4.9 months for patients treated with 
nanoliposomal irinotecan alone, demonstrating a not 
significant difference versus the 5-fluorouracil arm. This 
study suggested the prognostic role of several factors, 
including factors reported in the first-line setting, such as 
performance status, liver metastases, albumin levels and 
baseline CA 19.9 value (2,3). Of note, patients with adverse 
prognostic factors allocated in the combination arm had 
lower hazard ratio than patients who received 5-fluorouracil, 
suggesting the use of a more aggressive treatment in this 
subgroup of patients.
Remarkably, most of the secondary endpoints were met: 
a statistically significant difference was indeed reported in 
progression-free survival, time-to-treatment failure, response 
rate and CA 19.9 decrease. This new treatment can therefore 
be considered a new therapeutic option in second-line setting 
in patients pre-treated with gemcitabine or gemcitabine-
based combination, but some important consideration 
should be done. Firstly, the combination treatment showed 
a higher rate of grade 3 or 4 neutropenia: 27% versus 
15% of nanoliposomal irinotecan monotherapy and 1% of 
5-fluorouracil monotherapy. Furthermore, 3% of the patients 
in the combination arm experienced neutropenic sepsis. 
The choice of 5-fluorouracil as control arm has been 
correct from a methodological point of view, although its 
current use in clinical practice, with patients with good 
performance status, suggests a diffuse use of combinations 
in second-line setting (8-10). However, the use of the same 
control as in the CONKO-003 trial makes some indirect 
comparisons possible. The control arm performed better 
in this trial than in CONKO-003 with regards to overall 
survival (4.2 vs. 3.3 months), and in both cases these 
data were reliable and consistent with data derived from 
literature. Still, the survival reported for experimental arm 
in these trials was almost superimposable: 6.1 months in the 
nanoliposomal irinotecan and 5-fluorouracil and 5.9 months 
in the OFF combination, respectively. 
Table 1 summarizes the main characteristic of the trials 
CONKO-003, PANCREOX and NAPOLI-1. Of note, the 
selection criteria of the patients in these studies are quite 
different: in the CONKO-003 trial the patients were all 
treated in first line treatment for advanced disease (either 
locally advanced or metastatic), while in the NAPOLI-1 
trial also patients progressed within 6 months from 
adjuvant/neoadjuvant treatment were included. So, if on 
one hand we can say that in the NAPOLI-1 trial all the 
patients were metastatic at the time of randomization, while 
Table 1 Main characteristic of trials CONKO-003, PANCREOX, NAPOLI-1
Characteristic CONKO-003 PANCREOX NAPOLI-1
No. of patients 168 (77 OFF/91 FF) 108 (54 mFOLFOX6/54 FU/LV) 417 (151 NAL-IRI*/149 FU/FA**/117 NAL-IRI + FU/FA)
Regimens OFF; FF mFOLFOX-6; FU/LV NAL-IRI + FU/FA; FU/FA; NAL-IRI
Overall survival 5.9 months; 3.3 months 6.1 months; 9.9 months 6.1 months; 4.2 months; 4.9 months
FF, folinic acid and fluorouracil; FOLFOX, folinic acid (leucovorin), 5-fluorouracil and oxaliplatin; FU/FA, 5-fluororacil and folinic acid;  
FU/LV, 5-fluororacil and leucovorin; NAL-IRI, nanoliposomal irinotecan; OFF, oxaliplatin, 5-fluorouracil and folinic acid. *, nanoliposomal  
irinotecan; **, 5-fluororacil and folinic acid.
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in the CONKO-003 about 12% of patients were locally 
advanced, on the other hand the setting of treatment of the 
previous gemcitabine-based therapy was not specified in 
NAPOLI-1 trial leading to enrollment of a relatively not 
homogeneous population including patients progressed 
after an adjuvant treatment and patients largely pretreated 
in the metastatic setting (about 30% of patients had indeed 
received 2 or more lines for metastatic disease). 
Taking into account the current use of nab-paclitaxel in 
first-line setting and the neurotoxicity that derives from 
this therapy, the use of nanoliposomal irinotecan in second-
line setting seems to have less neurological side effects 
than oxaliplatin, however, the hematologic toxicity was not 
negligible in the NAPOLI-1 trial. 
Finally, data about the use of irinotecan or FOLFIRI 
regimen derive from little, prospective or retrospective 
reports, and at today no phase III trial has investigated this 
regimen in this setting (11-15).
Second-line treatment after FOLFIRINOX first-
line
There is currently no standard in second-line treatment for 
patients progressed on the triplet regimen. In the French 
phase III trial 80 patients in the “FOLFIRINOX group” 
and 85 patients in the “gemcitabine group” underwent a 
second-line treatment. In particular, in the FOLFIRINOX 
arm, gemcitabine (in 82.5% of cases) or a gemcitabine-
based combination (in 12.5%) were used as a second-line 
treatment (2), but no difference in second-line OS was 
noted between the two arms (i.e., 4.4 months each). 
Several retrospective series evaluated the use of a second-
line treatment with no conclusive results (8-10). A prospective 
French trial enrolled patients to receive gemcitabine and 
nab-paclitaxel as second-line treatment after FOLFIRINOX 
with encouraging results: 57 patients were treated, obtaining 
a disease control rate of 58%, and an objective response 
rate of 17.5%. Median overall survival (OS) was 8.8 months 
and median progression-free survival was 5.1 months (16). 
Other data about the use of gemcitabine and nab-paclitaxel 
combination derive from retrospective reports (17,18). 
Prospective phase III trials are therefore urgently needed for 
the identification of the standard second-line treatment after 
the triplet-drug regimen.
Future perspectives
Considering the latest news in the second-line treatment 
and the results  of  CONKO-003,  NAPOLI-1 and 
PANCREOX trials, further studies should evaluate the 
role of the combination of 5-fluorouracil and oxaliplatin 
in second-line setting in a larger, multicenter study, taking 
into account the new standard regimens in first-line 
treatment and using a more feasible schedule. However, 
the availability of two main options in first-line setting, 
deriving from phase III randomized trials, without direct 
comparisons between FOLFIRINOX or modified schedules 
and gemcitabine-nab-paclitaxel combination, makes the 
choice of second-line treatment more difficult, depending 
mostly on the choice of first-line.
No predictive factors of response at today can help 
clinicians in the choice of first-line treatments, which is 
actually based on clinical, patient or disease-related, factors. 
Biomarkers that might guide these therapies are urgently 
warranted and might be useful also in the second-line 
setting (19).
Furthermore, given all the recent diagnostics and 
prognostics improvements in a disease that had almost no 
treatment available until few years ago, the real issue is not 
only the search for the best second-line treatment, but, 
the identification of the optimal sequence of treatment, 
considering the aggressive and rapidly progressing nature of 
pancreatic cancer.
Finally, in the design of possible randomized studies 
aimed at the individuation of the ideal sequence-strategy, 
it should be taken into account the further change of the 
landscape that might derive from ongoing trials evaluating 
the triplet regimen FOLFIRINOX, FOLFOXIRI and 
the combination of gemcitabine and nab-paclitaxel in the 
adjuvant setting (20-22).
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